 MENLO PARK, Calif., March 29, 2021 GLOBE NEWSWIRE -- CohBar, Inc. NASDAQ: CWBR, a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced the completion of enrollment in the Phase 1b stage of the CB4211 clinical study for nonalcoholic steatohepatitis NASH and obesity. The company currently expects topline data at the end of the second quarter based on projected timing of the last subject visit and other factors. The company plans to announce the completion of the last subject visit, which is currently anticipated in April 2021. For more information, please join the companys quarterly call on March 30, 2021 at 5:00pm ET2:00pm PT. 